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Available online 15 May 2013AbstractBackground: Lidocaine is commonly used for rapid sequence intubation (RSI) in emergency departments. Its benefits remain controversial.
Traditional regression methods are commonly used to draw causal inferences. Propensity score matching based method, could be the solution for
studies with limited sample size.
Aim: To re-examine the association between postintubation hypotension (PIH) and lidocaine injection using different analysis methods.
Materials and methods: Secondary analysis was conducted of a retrospective cohort study with patients in emergency departments undergoing
RSI. Clinical information was recorded. PIH was defined as postintubation systolic blood pressure of <90 mmHg. Based on the propensity score
of having lidocaine injection generated by several variables, matching methods were applied and a comparable control group generated.
Outcome models based on logistic regression were compared using the original and matched datasets.
Results: Among 149 patients who received RSI agents, 28 developed PIH. Among 120 who received lidocaine injection, 27 developed PIH, as
did one the 29 patients who did not receive lidocaine. Lidocaine was not significantly associated with PIH in the traditional regression model
adjusting preintubation systolic blood pressure  140 mmHg, underlying history of chronic obstructive pulmonary disease, ongoing septic
status, and body weight. After 1:5 nearest matching with replacement based on the propensity score, most measurable potential confounders
were comparable in lidocaine-treated and control groups, except ongoing heart disease (e.g., atrial fibrillation and coronary artery disease). In the
subsequent logistic regression model adjusted for ongoing heart disease in the matched dataset, lidocaine was significantly associated with PIH.
Conclusion: Lidocaine injection could be associated with PIH; however, further investigation is needed. Alternative statistical methods should be
considered when making a causal inference.
Copyright  2013, Taiwan Society of Emergency Medicine. Published by Elsevier Taiwan LLC. All rights reserved.
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Many patients with airway compromise admitted to emer-
gency departments are difficult to manage because they are* Corresponding author. Emergency Department, Chang-Gung Memorial
Hospital at Linko, 5 Fuxing Street, Guishan Township, Taoyuan County 333,
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http://dx.doi.org/10.1016/j.jacme.2013.02.001either uncooperative or in an unrestrained position. Therefore,
development of a safe and rapid method to achieve airway
control is critical for improving the prognosis of these patients.1
Rapid sequence intubation (RSI) has high success rate2e9 and
airway control is achieved faster in patients when RSI is used.
Furthermore, RSI reduces the complications of intubation, such
as aspiration, hypoxemia, laryngospasm, and bronchospasm,
and prevents further cervical injury. Some immediate compli-
cations after RSI include hypoxemia, transient decrease inMedicine. Published by Elsevier Taiwan LLC. All rights reserved.
34 M.-T. Chiu et al. / Journal of Acute Medicine 3 (2013) 33e38systolic blood pressure, arrhythmia, and even death3e5,7,8 but
few studies10,11 have reported adverse outcomes after RSI.
Lidocaine is a prerequisite premedication agent during RSI
for attenuating airway reaction and resistance,12,13 reducing
cough reflex and preventing increase in intracranial pressure
(ICP) in the case of head injury.14,15 Although some studies
have reported16 that lidocaine reduced secondary brain injury
by decreasing cerebral flow, cerebral vascular resistance, and
cerebral metabolism, and by stabilizing neuronal membranes
by acting as a sodium channel blocker, other studies indi-
cate17,18 that lidocaine increases heart rate and blood pressure,
decreases the mean arterial pressure, and decreases perfusion
pressure leading to poor neurological outcome in cases of
acute stroke. The advantages and disadvantages of lidocaine
are still controversial.19 In a previous study,11 we identified
four independent risk factors of hypotension after RSI using
the traditional regression method, but administration of lido-
caine failed to achieve statistical significance.
In this study, we re-examined the causal relationship be-
tween lidocaine administration and postintubation hypotension
(PIH) using a case-control study. We also compared the
traditional regression methods with a propensity score
matching based method for causal inference. The latter
method might have an advantage in evaluating the effects ofTable 1
Characteristics of postintubation hypotension (PIH) and non-PIH patients.
Variable Mean/median (SD/IQR) PIH (n ¼ 28)
Demographics
Male (n, %) 18 (64)
Age (year) 73 (55e79)
Weight (kg) 54 (46e58)
Pre-RSI vital signs
SBP (mmHg) 124 (110e146)
DBP (mmHg) 70 (61e78)
HR (beat/min)* 114 (97e135)
RR (breaths/min)** 24 (20e32)
SaO2 (%)*** 93 (85e96)
Post-RSI vital signs
SBP (mmHg) 70 (22)
DBP (mmHg) 42 (37e47)
HR (beats/min) 102 (35)
Laboratory tests
WBC (109/L) 12.7 (8.9e14.7)
Hemoglobin (g/L) 115 (27)
Creatinine (mg/L) 15 (8e39)
Albumin (g/L) 25 (8)
Potassium (mEq/L) 3.9 (3.5e4.4)
Sodium (mEq/L) 136 (134e139)
Glucose (g/L) 1.31 (1.06e1.82)
Arterial pH 7.33 (7.23e7.41)
Arterial pCO2 (mM) 42.8 (28.5e61.5)






* ¼ 2 missing data; ** ¼ 27 missing data; *** ¼ 5 missing data.
DBP ¼ diastolic blood pressure; HR ¼ heart rate; IQR ¼ interquartile range; RR ¼
SBP ¼ systolic blood pressure; SD ¼ standard deviation; WBC ¼ white blood cetreatments on health outcomes and other clinical research
using observational data with limited sample size.
2. Materials and methods2.1. Study design and settingThis is a secondary data analysis of a caseecontrol study.
The data obtained between March 2002 and September 2002
from all adult nontrauma patients who received RSI in the
emergency department of a tertiary 3700-bed medical center
were retrospectively analyzed. This study was approved by the
Ethics Committee on Human Research of the hospital and was
exempt from the requirement of obtaining informed consent
under agreement.2.2. Patient selection and data collectionInclusion criteria for selection of patients were patients
older than 18 years who were seen in the emergency depart-
ment requiring emergency airway management and who un-
derwent RSI during the study period. The exclusion criteria
included initial systolic blood pressure < 90 mmHg, apparent
shock, ventricular arrhythmia, trauma as cause of injury,NonePIH (n ¼ 121) Total (n ¼ 149) p
79 (65) 97 (65) 0.92
71 (58e79) 72 (58e79) 0.80
57 (49e64) 55 (49e63) 0.055
148 (122e163) 142 (119e161) 0.004
74 (62e87) 73 (62e86) 0.10
107 (97e125) 108 (97e126) 0.82
28 (22e32) 27 (21e32) 0.35
89 (82e96) 89 (82e98) 0.66
141 (36) 127 (44) <0.001
68 (53e82) 61 (48e79) <0.001
111 (26) 110 (28) 0.14
10.9 (7.3e15.3) 11.2 (7.6e15) 0.48
117 (29) 116 (29) 0.83
13 (10e21) 13 (9e23) 0.73
29 (8) 28 (8) 0.03
4.2 (3.6e4.9) 4.1 (3.6e4.7) 0.13
138 (133e140) 138 (133e140) 0.29
1.43 (1.15e2.31) 1.38 (1.13e2.21) 0.19
7.33 (7.25e7.42) 7.33 (7.24e7.42) 0.78
38.3 (29.7e57) 38.5 (29.7e57.5) 0.95
22.6 (8.5) 22.6 (8.7) 0.94
100 (70e100) 95 (70e100) 0.27
50 (50e50) 50 (40e50) 0.10
50 (50e70) 50 (50e50) 0.84
5 (5e5) 5 (5e5) 0.29
respiratory rate; RSI ¼ rapid sequence intubation; SaO2 ¼ oxygen saturation;
lls.
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rest, hypoxemia (pulse oximetry reading, < 90%), esophageal
intubation, tube malposition, and more than three attempts at
intubation.
Standardized RSI includes preparation, preoxygenation,
pretreatment, paralysis with induction, placement of the tube,
and postintubation management. The most common pretreat-
ment medications used during RSI were lidocaine (1e1.5 mg/
kg), midazolam (0.05e0.1 mg/kg), ketamine (1e2 mg/kg), and
rocuronium (0.8e1.2 mg/kg).
The included patients were first divided into two groups;
the hypotension group and the normal control group. Hypo-
tension was defined as pre-RSI systolic blood
pressure < 90 mmHg no earlier than 5 minutes prior to intu-
bation. The data were collected in four categories: (1) basic
anthropometrics, including age, sex, body weight, underlying
diagnosis, and ongoing disease; (2) vital signs prior to and
after RSI, including heart rate and blood pressure; (3) blood
biochemistry, including white blood cell count, levels of he-
moglobin, sodium, potassium, albumin, creatinine, and arterial
blood gas; and (4) drugs administered during RSI, including
their dose. Next, the patients were reclassified into “patients
with lidocaine” and “patients without lidocaine” for sequential
propensity score matching. The relationship between lidocaine
administration and postintubation hypotension was analyzed.2.3. Statistical analysisTable 2





OR (95% CI) p
Ongoing disease
Malignancy 3 13 1.00 (0.26e3.76) 0.99
CHF 4 17 1.02 (0.31e3.30) 1.00
Other heart disease 6 25 1.05 (0.38e2.86) 0.93
COPD 7 12 3.00 (1.06e8.51) 0.05
Pneumonia 14 66 0.83 (0.37e1.90) 0.66
CVA 0 9 0.46 (0.01e3.40) 0.21
Liver disease 3 12 1.09 (0.29e4.15) 1.00
Renal disease 5 14 1.66 (0.54e5.07) 0.36
Seizure disorder 0 3 1.46 (0.03e18.90) 1.00
Sepsis 9 8 6.69 (2.29e19.47) <0.001
Intoxication 0 5 0.86 (0.02e8.15) 0.58
UGI bleeding 5 23 0.93 (0.31e2.67) 0.88
Underlying disease
COPD 7 18 1.91 (0.71e5.14) 0.26
CVA 2 15 0.54 (0.12e2.50) 0.53
DM 6 33 0.73 (0.27e1.95) 0.53
HTN 10 51 0.76 (0.33e1.79) 0.53
Malignancy 2 14 0.59 (0.81e10.57) 0.74
Renal disease 5 18 1.24 (0.42e3.67) 0.77
Heart disease 6 17 1.67 (0.59e4.71) 0.38
Prescription of RSI medications
Lidocaine 27 93 8.13 (1.06e62.53) 0.02
Rocurorium 28 111 2.43 (0.32e109.40) 0.21
Ketamine 4 15 1.18 (0.36e3.87) 0.76
Midazolam 11 59 0.68 (0.29e1.57) 0.37
CHF ¼ congestive heart failure CI ¼ confidence interval; COPD ¼ chronic
obstructive pulmonary disease; CVA ¼ cerebrovascular accident;
DM ¼ diabetes mellitus; HTN ¼ hypertension; OR ¼ odds ratio;
UGIB ¼ upper gastrointestinal tract bleeding.Biostatistical analysis was performed using Chi-square test
or Fisher’s test for categorical variables and Student t test of
Wilcoxon rank-sum test for continuous variables. A p value
<0.05 was considered statically significant. Univariate anal-
ysis and multiple logistic regression analysis were used to
analyze the factors influencing the occurrence of hypotension
after RSI. Adjustment for confounding variables was per-
formed using two methods: traditional logistic regression
method; and propensity score matching based method, which
used the available variables to predict whether patients
receiving lidocaine had similar propensity scores. To reduce
treatment selection bias for RSI and any other related potential
confounding variable, the baseline characteristics of the pa-
tient were adjusted using propensity scores. The propensity
scores for receiving lidocaine as one of the pretreatment
medications were estimated using multiple logistic regression
analysis, including the following variables: age, sex, body
weight, vital signs prior to intubation (i.e., oxygen saturation,
pulse rate, respiratory rate, and blood pressure), underlying
illness (i.e., diabetes, hypertension, stroke, chronic obstructive
pulmonary disease, lung cancer, coronary artery disease, and
chronic kidney disease), and ongoing disease, including sepsis,
trauma, chronic obstructive pulmonary disease (COPD) with
acute exacerbation, old stroke [old cerebrovascular accident
(CVA)], diabetes mellitus (DM), hypertension (HTN), renal
disease, cancer, and heart disease. Ongoing diseases included
COPD, sepsis, congestive heart failure (CHF), CVA, acute
myocardial infarction (AMI), liver disease, pneumonia, renal
disease, seizure disorder, upper gastrointestinal tract bleeding(UGIB), intoxication, and malignancy. The Akaike informa-
tion criterion (AIC) was also used.
3. Results
Of the 149 patients from whom data was collected, 28
patients developed PIH. The majority in both the PIH and
control groups were male, and the average age was 72 years.
The body weight of patients in the PIH group was slightly
lower than, but not significantly different from, that of patients
in the control group. Prior to receiving RSI, patients in the PIH
group had significantly lower systolic blood pressure than
those in the control group (124 mmHg vs. 148 mmHg,
p ¼ 0.004). The systolic and diastolic blood pressures after
RSI were significantly lower in the PIH group than in the
control group (70 mmHg vs. 141 mmHg, p < 0.001, Table 1).
Further analysis indicated that COPD [odds ratio (OR) 3.00,
95% confidence interval (CI) 1.06e8.51, p ¼ 0.05] and sepsis
(OR 6.69, 95% CI 2.29e19.47, p < 0.001) were more sig-
nificant predictors of PIH than were ongoing diseases. The
level of albumin in the PIH group, 25 g/L, was markedly lower
than that in the control group, 29 g/L ( p ¼ 0.003). Lidocaine
as one of the pretreatment medications was found to be
associated with PIH (OR 8.13, 95% CI 1.06e62.53, p ¼ 0.02,
Table 2). Of the 120 patients who received lidocaine injection,
27 developed PIH, whereas one of the 29 patients who did not
36 M.-T. Chiu et al. / Journal of Acute Medicine 3 (2013) 33e38receive lidocaine developed PIH. However, the dose of lido-
caine adjusted for body weight showed no significant differ-
ences between groups (Table 1).
Patients receiving lidocaine were further matched with
those who did not receive lidocaine using a propensity score
(Table 3). The c-statistic for the propensity score model
indicated good decimation (data not shown). After propensity
score matching, the lidocaine group became more similar to
the group receiving no lidocaine. As indicated in Table 3, the
lidocaine group then had more similar distributions of de-
mographics (e.g., sex), underlying disease (e.g., COPD, CVA,
HTN, and malignancy), ongoing diseases (e.g., pneumonia,
CVA, sepsis, and intoxication), and pretreatment medication
(e.g., rocurorium). However, the matched patients with lido-
caine were still statistically different from those with no
lidocaine in that they were more likely to be older (73 years
vs. 60 years, p ¼ 0.03), and to have ongoing other heart dis-
eases (OR 4.82, p ¼ 0.03). Other variables remained insig-
nificantly different between groups (Table 4).
The traditional regression method was used to adjust pre-
intubation hypotension (SBP < 140 mmHg), underlying
COPD history, ongoing septic status, and body weight as
confounders (Model 1, Table 5). In this multiple logistic
regression model, the administration of lidocaine as a pre-
treatment medication was found to be associated with PIH,
although this was not statistically significant (OR 5.51,
p ¼ 0.11). In Model 2, the association between administrationTable 3
Characteristics of patients with and without lidocaine.
Variable Mean/median (SD/IQR) Lidocaine (n ¼ 120) No lidocai
Male (n, %) 76 (63) 21 (72
Age (year) 73 (61e80) 60 (50
Weight (kg) 54 (49e64) 57 (54
Pre-RSI vital signs
SBP (mmHg) 142 (119e163) 142 (12
DBP (mmHg) 73 (62e85) 74 (64
HR (beats/min)* 110 (98e129) 101 (90
RR (breaths/min)* 28 (20e33) 25 (22
SaO2 (%)** 90 (82e96) 88 (83
Post-RSI vital signs
SBP (mmHg) 125 (44) 132 (44
DBP (mmHg) 61 (48e79) 64 (50
HR (beats/min) 110 (27) 106 (31
Laboratory tests
WBC (109/L ) 11.2 (7.7e15.1) 11.7 (6.4
Hemoglobin(g/L) 116 (29) 119 (28
Creatinine (mg/L) 14 (8e24) 12 (1e
Albumin (g/L) 28 (8) 28 (8)
Potassium (mEq/L) 4.1 (3.5e4.7) 4.2 (3.8
Sodium (mEq/L) 138 (133e140) 138 (13
Glucose (mg/L) 1.43 (1.15e2.31) 1.25 (1.0
Arterial pH 7.33 (7.25e7.42) 7.35 (7.2
Arterial pCO2 (mM) 38.2 (29.6e58.1) 38.5 (32
Drug dosage (mg)
Rocurorium 50 (40e50) 50 (50
Ketamine 50 (50e50) 27.5 (5e
Midazolam 5 (5e5) 5 (5e
* ¼ 2 missing data; ** ¼ 27 missing data.
DBP ¼ diastolic blood pressure; HR ¼ heart rate; IQR ¼ interquartile range; RR ¼
SBP ¼ systolic blood pressure; SD ¼ standard deviation; WBC ¼ white blood ceof lidocaine and PIH were analyzed using propensity score
matching of the lidocaine group versus the nonlidocaine
group, in which lidocaine administration was statistically
significantly associated with PIH (OR 9.33, p ¼ 0.036, Table
5). In order to adjust the residual confounding caused by age
and ongoing other heart diseases, these statistical models were
further established and the fitness of the models examined by
AIC (Models 3 and 4, Table 5). The association between
lidocaine administration and PIH remained statistically sig-
nificant in these two models (OR: 10.69 and 11.55, p ¼ 0.027
and 0.024, respectively). According to the AIC, the traditional
logistical regression model was the least optimal statistical
model, and the propensity score matched logistic regression
models showed better performance (AIC 126 vs. 71, 73 and
74, respectively).
4. Discussion
In this study, we illustrated the effect of different statistical
models such as traditional logistic regression and propensity
score based logistic regression models. We addressed the
possible prognostic factors for hypotension after RSI, which
included vital signs prior to RSI, ongoing COPD and sepsis,
and hypoalbuminemia. In a previous study,20 we reported that
the frequency and dose of lidocaine were higher in the hy-
potension group than in the control group. However, the
relationship between lidocaine administration and PIHne (n ¼ 29) p Matched lidocaine (n ¼ 58) p
) 0.36 39 (68)
e75) 0.005 73 (60e80) 0.03
e62) 0.37 54 (48e65) 0.35
1e154) 0.84 141 (119e159) 0.91
e90) 0.58 73 (62e84) 0.66
e118) 0.12 108 (97e125) 0.21
e31) 0.69 27 (20e34) 0.89
e95) 0.77 94 (83e100) 0.77
) 0.49 124 (42) 0.42
e80) 0.81 60 (50e75) 0.77
) 0.57 106 (27) 0.95
e14.9) 0.95 9.8 (6.9e15.5) 0.76
) 0.60 116 (3.0) 0.70
17) 0.64 14 (8e21) 0.64
0.92 28 (8) 0.92
e4.9) 0.35 4.1 (3.7e4.9) 0.61
5e141) 0.75 138 (134e140) 0.71
6e2.00) 0.20 1.61 (1.15e2.37) 0.10
4e7.42) 0.66 7.37 (7.28e7.46) 0.20
e48) 0.93 36.3 (27.7e50.9) 0.41
e50) 0.16 50 (50e50) 0.26
50) 0.26 50 (50e60) 0.29
5) 0.91 5 (5e5) 0.81
respiratory rate; RSI ¼ rapid sequence intubation; SaO2 ¼ oxygen saturation;
lls.
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OR (95% CI) p Matched lidocaine
(n ¼ 58)
OR (95% CI) p
Ongoing disease
Malignancy 13 3 1.05 (0.26e6.17) 0.94 6 1.02 (0.24e4.41) 0.98
CHF 16 5 0.74 (0.25e2.21) 0.59 10 1.02 (0.31e3.33) 0.97
Other heart 29 2 4.30 (0.97e9.20) 0.04 15 4.82 (1.02e22.78) 0.03
COPD 17 2 2.25 (0.49e10.34) 0.29 2 2.25 (0.37e9.74) 0.29
Pneumonia 68 12 1.85 (0.81e4.21) 0.14 31 1.67 (0.68e4.17) 0.25
CVA 8 1 2.00 (0.24e6.66) 0.51 2 1.02 (0.09e11.72) 0.99
Liver 10 5 0.44 (0.14e1.39) 0.15 6 0.56 (0.16e2.04) 0.38
Renal 16 3 1.33 (0.36e4.92) 0.67 9 1.63 (0.40e6.53) 0.49
Seizure 3 0 0.72 (0.06e39.02) 1.00 0 0.51 (0.01e31.92) NA
Sepsis 16 1 4.31 (0.55e33.9) 0.13 4 2.11 (0.23e19.82) 0.50
Intoxication 3 2 0.35 (0.06e2.17) 0.24 3 0.75 (0.12e4.76) 0.76
UGIB 23 5 1.14 (0.39e3.30) 0.81 13 1.42 (0.45e4.46) 0.55
Underlying disease
COPD 22 3 1.95 (0.54e7.01) 0.30 8 1.41 (0.35e5.79) 0.63
CVA 15 2 1.95 (0.42e9.04) 0.39 6 1.59 (0.30e8.41) 0.58
DM 32 7 1.14 (0.45e2.93) 0.78 18 1.45 (0.52e4.01) 0.47
HTN 53 8 2.08 (0.85e5.06) 0.10 23 1.78 (0.67e4.69) 0.24
Malignancy 6 3 0.44 (0.21e2.33) 0.25 5 0.83 (0.33e4.19) 0.81
Renal 19 4 1.18 (0.37e3.77) 0.78 9 1.17 (0.33e4.19) 0.81
Heart 20 3 1.73 (0.48e6.28) 0.40 5 0.83 (0.19e3.76) 0.81
RSI medication
Rocurorium 116 23 7.57 (1.98e28.95) <0.001 53 3.46 (0.89e13.42) 0.06
Ketamine 17 2 2.23 (0.49e10.24) 0.29 8 2.21 (0.44e11.13) 0.33
Midazolam 57 13 1.11 (0.49e2.51) 0.79 24 0.90 (0.36e2.20) 0.81
CHF ¼ congestive heart failure CI ¼ confidence interval; COPD ¼ chronic obstructive pulmonary disease; CVA ¼ cerebrovascular accident; DM ¼ diabetes
mellitus; HTN ¼ hypertension; OR ¼ odds ratio; UGIB ¼ upper gastrointestinal tract bleeding.
37M.-T. Chiu et al. / Journal of Acute Medicine 3 (2013) 33e38remained uncertain after adjustment for body weight.20 We
reanalyzed the same raw data and re-examined the relationship
between hypotension after RSI and the use of lidocaine using
propensity score matching. The results obtained by using this
method provided a different conclusion: that lidocaine as one
of the pretreatment medications for RSI might be, in fact,
associated with postintubation hypotension.
There are a number of pharmacological and physiological
processes underlying the association between lidocaine andTable 5
Tradition regression model versus propensity score matched logistic regression
models.a
Model 1 Model 2 Model 3 Model 4
Lidocaine
OR 5.51 9.33 10.69 11.55
95% CI 0.68e44.63 1.16e75.03 1.30e87.73 1.39e96.17
p 0.110 0.036 0.027 0.024
Other heart disease
OR 0.534 0.603





AIC 126 71 73 74
AIC ¼ Akaike information criterion; CI ¼ confidence interval; OR ¼ odds
ratio.
a Model 1: traditional regression model adjusting preintubation
SBP  140 mmHg, underlying chronic obstructive pulmonary disease history,
ongoing septic status, and body weight as confounders. Models 2e4: pro-
pensity score matched conditional logistic regression models.postintubation hypotension after RSI. The main effects of
lidocaine area decrease in the conductance of sodium chan-
nels, antiarrhythmic effects, sedation, and neural blockade.
Lidocaine blocks sodium channels through a “fast ineslow
out” mechanism that affects impulse conduction through the
heart and nerve tissue. This mechanism depresses Vmax (i.e.,
the rate of depolarization during Phase 0 of the cardiac action
potential) and may lead to re-entrant arrhythmias. Addition-
ally, conduction through the sinus and atrialeventricular nodes
may be suppressed. Therefore, the decreases in conduction
rate and force of contraction of the heart may contribute to
reduced cardiac output, resulting in hypotension.
We identified sepsis as one of the important prognostic
factors in PIH, because of the nature of the condition in pa-
tients. Maintaining hemodynamic stability in patients with
respiratory failure is important due to increased mortality
risk.21 Preintubation hypotension is associated with severe
complications and death after airway management.22 Simi-
larly, PIH during general anesthesia is related to increased
mortality.23 The reduced effective intravascular volumes in
patients with sepsis is the primary cause of circulatory insta-
bility and collapse.24 A sudden decrease in sympathetic tone
after intubation may cause extreme hemodynamic changes,
which further results in hypotension.25 In COPD, the mecha-
nism is similar. The decrease in sympathetic vascular tone
leads to hemodynamic compromise by reducing cardiac pa-
rameters of preload and afterload.11 Positive ventilation and
end-expiratory pressure have been found to reduce intratho-
racic pressure, which hinders venous return from peripheral
38 M.-T. Chiu et al. / Journal of Acute Medicine 3 (2013) 33e38circulation to right ventricle. This causes further deterioration
of the physiological status of the patients with COPD and can
result in profound hypotension.25
Albumin was another important prognostic factor for PIH.
The likely mechanism is that increased capillary membrane
permeability causes loss of intravascular colloid osmotic
pressure when fluid shifts into the tissues.26A previous study
indicated27 that patients with low body weight had higher
mortality rates than those with normal weight.
The propensity score matching based method can reduce
significant confounding factors. Because of the small sample size
in this study, the previous traditional logistic regression method
was not strong enough to demonstrate the barely significant effect
of lidocaine administration. In this study, we used the propensity
score matching method and matched the comparable patients
with similar demographics, underlying illnesses, and ongoing
illnesses, without sacrificing the power required in the statistical
model. Therefore, we hypothesized that the difference in the re-
sults between these methods could be because of the statistical
power.Another advantageof propensity scorematching is that the
two-step analysis can avoid bias. We incorporated a broad set of
controls for observed confounders and used propensity score
analysis, which removes some measured confounders to the
extent that they are correlated with the observed covariates.
Limitations of this study include small sample size and the
lack of evaluation of the interaction with other RSI agents and
ongoing or underlying illness. Better propensity matching is
required in future studies. This method cannot be generalized,
and thus a single-center study is not sufficient to provide
adequate evidence. Immeasurable confounding factors of this
study include physician preference and volume status. Posthoc
analysis, secondary data analysis, and the fact that the analyst
was not blinded to the study were other limitations. An
improved study design is required to get better results.
In conclusion, we suggest that lidocaine injection may be
associated with PIH in the performance of RSI. Emergency
physicians should carefully consider the indication for pre-
medication agents for RSI. In addition, researchers should
consider methods other than traditional statistical methods
when making causal inference.
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